Abstract Number: 0327 • ACR Convergence 2021
Lipoprotein(a) in Systemic Lupus Erythematosus Is Associated with History of Proteinuria and Renal Insufficiency
Background/Purpose: Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease. Cardiovascular disease is one of the leading causes of death in patients…Abstract Number: 0344 • ACR Convergence 2021
Anti-gAChR Antibody as a Novel Biomarker for Lupus Enteritis in Systemic Lupus Erythematosus
Background/Purpose: Anti-ganglionic nicotinic acetylcholine receptor (gAChR) antibody (Ab) is associated with widespread autonomic dysfunction in autoimmune autonomic ganglionopathy. Although it is also detected in several…Abstract Number: 0492 • ACR Convergence 2021
Racial Differences in Glucocorticoid Use Among Medicaid Beneficiaries with Incident Systemic Lupus Erythematosus
Background/Purpose: Glucocorticoids (GCs) are an integral part of systemic lupus erythematosus (SLE) treatment. Long-term use of GCs is associated with adverse effects. This study evaluated…Abstract Number: 0600 • ACR Convergence 2021
A Cohort Study of Retention in Ambulatory Lupus Care Among Medicare Patients with SLE-related Hospitalizations
Background/Purpose: In other conditions that require chronic management, poor retention in ambulatory care is associated with adverse outcomes. We previously identified that living in the…Abstract Number: 0777 • ACR Convergence 2021
Potential Biomarkers of Cognitive Impairment in the Context of Childhood-Onset Systemic Lupus Erythematosus
Background/Purpose: Cognitive complaints are common in children with childhood-onset systemic lupus erythematosus (cSLE), but neuropsychiatric lupus (NPSLE) remains challenging to diagnose and treat. To increase…Abstract Number: 0868 • ACR Convergence 2021
Cell-bound Complement Activation Products (CB-CAPs) Predicts Type 1 SLE Activity
Background/Purpose: SLE is a multisystem autoimmune disease that displays diverse manifestations that can be categorized into two broad types. Type 1 SLE activity includes inflammatory…Abstract Number: 0885 • ACR Convergence 2021
SLE Phenotypes Formed from Machine Learning and Their Associations with Cognitive Impairment
Background/Purpose: Cognitive impairment (CI) in SLE is a significant problem with limited treatment options. This is in part due to the uncertainty regarding the multifaceted…Abstract Number: 0972 • ACR Convergence 2021
Hypoxia Promotes the Expression of ADAM9 by Tubular Epithelial Cells Which Enhances TGF-β1 Activation and Promotes Tissue Fibrosis in Lupus Nephritis
Background/Purpose: Enhanced expression of transforming growth factor-beta (TGF-β) in the kidneys of patients with lupus nephritis (LN) can lead to progressive fibrosis, resulting in end-organ…Abstract Number: 1099 • ACR Convergence 2021
Characteristics and Outcomes of Myocardial Infarction in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Gout and Osteoarthritis Patients Using the National Inpatient Sample Database from 2002-2018
Background/Purpose: Patients with the autoimmune rheumatic disease have an increased risk of acute myocardial infarction (MI). Our study was designed to compare the prevalence, characteristics…Abstract Number: 1265 • ACR Convergence 2021
Paradoxical Effect of Vitamin D on Bone Mineral Density in SLE
Background/Purpose: Osteoporosis with fractures is consistently one of the top three items in the SLICC/ACR Damage Index in cohort studies internationally. As vitamin D insufficiency…Abstract Number: 1281 • ACR Convergence 2021
Longitudinal Association of Baseline Frailty with Patient-Reported Outcome Measures
Background/Purpose: Frailty has been associated with disability and mortality in systemic lupus erythematosus (SLE). While frailty is known to be associated with worse patient-reported outcome…Abstract Number: 1297 • ACR Convergence 2021
Factors Associated with Employment and Work Disability in Patients with SLE: A Nested Case-control Study
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organ systems and can vary in its manifestations between individuals. SLE…Abstract Number: 1459 • ACR Convergence 2021
Attainment of the Lupus Low Disease Activity State in Response to Anifrolumab in 2 Phase 3 Trials
Background/Purpose: The Lupus Low Disease Activity State (LLDAS), a treat-to-target (T2T) endpoint for SLE, is prospectively validated as protective from flares and damage accrual.1 LLDAS…Abstract Number: 1491 • ACR Convergence 2021
Single-cell Analysis of Paired Skin and Blood Samples from Patients with SLE and Cutaneous Lupus Suggests CD16+ DCs Arise from Non-classical Monocytes That Enter Nonlesional Skin, Undergo Type I IFN Education, and Engage in Extensive Crosstalk with Diverse Immune and Stromal Cell Types
Background/Purpose: Cutaneous lupus erythematosus (CLE) is an incompletely understood autoimmune disease that can occur in isolation or in the context of SLE. CLE is often…Abstract Number: 1592 • ACR Convergence 2021
ACT for Lupus: Pilot Study of a Novel Acceptance and Commitment Therapy (ACT) Online Program to Support Patients with Lupus During the COVID-19 Pandemic
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic disease associated with significant symptom burden, including fatigue, anxiety, depression, pain, and negative impacts on health-related quality…
- « Previous Page
- 1
- …
- 93
- 94
- 95
- 96
- 97
- …
- 150
- Next Page »